Pfizer for Kids: Dodgy Data and Conflicts of Interest

[Geee]

Brownstone Institute

The Joint Committee on Vaccination and Immunisation (JCVI), an independent group of experts who advise the UK’s government health departments on immunisations published a report on 16 February stating, ‘JCVI advises a non-urgent offer at two 10mcg doses of the Pfizer-BioNTech Covid-19 vaccine to children aged 5 to 11 years of age who are not in a clinical risk group.’

I recently interviewed Dr Tony Hinton, a retired NHS surgeon of 35 years, regarding the JCVI’s recent statement, which I posted on my substack. Dr Hinton found it to be full of contradictions and the CDC data that the JCVI relied upon to be skewed, in comparison to data recorded in a Hong Kong study, yielding significantly different vaccine-related myocarditis rates in children.

The following day, a breaking news story by The New York Times, came to my attention, what it revealed helps explain why the CDC data appears to be so irregular. The article exposed the fact that the CDC (Centre for Disease Control in the US) had been withholding vast amounts of Covid data from the public. It stated: ‘Two full years into the pandemic, the agency leading the country’s response to the public health emergency has published only a tiny fraction of the data it has collected.’

The article went on to quote, Samuel Scarpino, managing director of pathogen surveillance at the Rockefeller Foundation’s Pandemic Prevention Institute, who said, “The C.D.C. is a political organization as much as it is a public health organization.”

His bombshell statement helps make a strong case that the US Covid policy (including the vaccine programme) has been governed by politics all along, rather than the science.

Furthermore, the JCVI and the MHRA have relied unquestioningly on Pfizer’s clinical trial data to authorise and recommend the experimental Pfizer-BioNTech vaccine comprising of the novel lipid nanoparticle formulation containing nucleoside-modified mRNA.

The same clinical trial data that’s been cast into serious doubt by recent whistle-blowers, like Brook Jackson, the regional director of several of the clinical trial sites used in Pfizer’s pivotal Phase III trial, which the BMJ covered, last November.

The Pfizer and BioNTech funded evaluation report

What’s highly concerning is that the study published in the NEJM (The New England Journal of Medicine) which the JCVI included in their recent report, when evaluating vaccine safety of the Pfizer-BioNTech (BNT162b2) vaccine in children aged 5-11- was entirely funded by Pfizer and BioNtech, with the authors of the study directly working for either company. It’s also disturbing, how nobody at the JCVI would have sounded the alarm bells of ‘conflict of interest’ but instead chose to remain silent and rely on that far from independent study.

The Pfizer and BioNTech funded report states that ‘Covid-19 vaccines are urgently needed in children younger than 12 years of age’ and of course concludes that the Pfizer-BioNTech (BNT162b2) vaccine is ‘safe, immunogenic, and efficacious in children 5 to 11 years of age.’ The report alarmingly states, ‘Without effective Covid-19 vaccines for this age group, children could potentially become ongoing reservoirs of infection and sources of newly emerging variants.’